Sunitinib adverse events in metastatic renal cell carcinoma: A meta-analysis

International Journal of Clinical Oncology

Volumn 18, Issue 6, 2013, Pages 1060-1069

  Ibrahim, Ezzeldin M ^a   Kazkaz, Ghieth A ^a   Abouelkhair, Khaled M ^a   Bayer, Ali M ^a   Elmasri, Osama A ^a  

^a International Medical Center   (Saudi Arabia)

Author keywords

Adverse events; Renal cell carcinoma; Sunitinib

Indexed keywords

CREATININE; SUNITINIB;

ADVERSE OUTCOME; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFECT; DRUG SAFETY; EPISTAXIS; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOTHYROIDISM; KIDNEY MALFORMATION; KIDNEY METASTASIS; LIMB PAIN; LIVER DISEASE; META ANALYSIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

CARCINOMA, RENAL CELL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INDOLES; KIDNEY NEOPLASMS; PYRROLES;

EID: 84891486967     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0497-2     Document Type: Article

References (57)

1. Rini BI, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373(9669):1119-1132. doi: 10.1016/S0140-6736(09)60229-4
2. Flanigan RC, Mickisch G, Sylvester R et al (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171(3):1071-1076
3. Fyfe G, Fisher RI, Rosenberg SA et al (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13(3):688-696
4. McDermott DF, Regan MM, Clark JI et al (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23(1):133-141. doi: 10.1200/jco.2005.03.206
5. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115-124. doi: 10.1056/NEJMoa065044
6. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271-2281. doi: 10.1056/NEJMoa066838
7. Escudier B, Szczylik C, Hutson TE et al (2009) Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27(8):1280-1289. doi: 10.1200/jco.2008.19.3342
8. Sun M, Lughezzani G, Perrotte P et al (2010) Treatment of metastatic renal cell carcinoma. Nat Rev Urol 7(6):327-338. doi: 10.1038/nrurol.2010.57
9. http://www.cancer.gov/cancertopics/druginfo/kidneycancer. Accessed 10 Sep 2012
10. Motzer RJ, Michaelson MD, Redman BG et al (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24(1):16-24. doi: 10.1200/JCO.2005.02.2574
11. Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9(1):327-337
12. Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584-3590. doi: 10.1200/JCO.2008.20. 1293
13. Gore ME, Szczylik C, Porta C et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10(8):757-763. doi: 10.1016/s1470-2045(09)70162-7
14. Porta C, Paglino C, Imarisio I et al (2011) Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC Cancer 11:105. doi: 10.1186/1471-2407- 11-105
15. Escudier B, Roigas J, Gillessen S et al (2009) Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 27(25):4068-4075. doi: 10.1200/jco.2008.20.5476
16. Rini BI, Michaelson MD, Rosenberg JE et al (2008) Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26(22):3743-3748. doi: 10.1200/jco.2007.15.5416
17. Barrios CH, Hernandez-Barajas D, Brown MP et al (2012) Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer (Phila) 118(5):1252-1259. doi: 10.1002/cncr.26440
18. Kontovinis LF, Papazisis KT, Touplikioti P et al (2009) Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 9:82. doi: 10.1186/1471-2407-9-82
19. Slim K, Nini E, Forestier D et al (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. A N Z J Surg 73(9):712-716 (pii: 2748)
20. Gallo V, Egger M, McCormack V et al (2011) STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): an extension of the STROBE Statement. PLoS Med 8(10):e1001117. doi: 10.1371/journal.pmed.1001117
21. Clayton D, Hills M (1993) Statistical models in epidemiology. Oxford University Press, Oxford
22. Pirani M, Marcheselli R, Marcheselli L et al (2011) Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. Ann Oncol 22(8):1845-1858. doi: 10.1093/annonc/mdq697
23. Alder N, Fenty J, Warren F et al (2006) Meta-analysis of mortality and cancer incidence among workers in the synthetic rubber-producing industry. Am J Epidemiol 164(5):405-420. doi: 10.1093/aje/kwj252
24. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539-1558. doi: 10.1002/sim.1186
25. Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557-560. doi: 10.1136/bmj.327.7414.557
26. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177-188. doi: 10.1016/0197-2456(86)90046-2
27. Donders AR, van der Heijden GJ, Stijnen T et al (2006) Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 59(10):1087-1091. doi: 10.1016/j.jclinepi.2006.01.014
28. Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629-634
29. Moher D, Liberati A, Tetzlaff J et al (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8(5):336-341. doi: 10.1016/j.ijsu.2010.02.007
30. Motzer RJ, Rini BI, Bukowski RM et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21):2516-2524. doi: 10.1001/jama.295.21.2516
31. Ansari J, Fatima A, Fernando K et al (2010) Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience. Oncol Rep 24(2):507-510
32. Tomita Y, Shinohara N, Yuasa T et al (2010) Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 40(12):1166-1172. doi: 10.1093/jjco/hyq146
33. Josephs D, Hutson TE, Cowey CL et al (2011) Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int 108(8):1279-1283. doi: 10.1111/j.1464-410X.2010.09990.x
34. Motzer RJ, Hutson TE, Olsen MR et al (2012) Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 30(12):1371-1377. doi: 10.1200/jco.2011.36.4133
35. Di Lorenzo G, Autorino R, Bruni G et al (2009) Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 20(9):1535-1542. doi: 10.1093/annonc/mdp025
36. Cairns P (2010) Renal cell carcinoma. Cancer Biomark 9(1-6):461-473. doi: 10.3233/CBM-2011-0176
37. Ng CS, Wood CG, Silverman PM et al (2008) Renal cell carcinoma: diagnosis, staging, and surveillance. AJR Am J Roentgenol 191(4):1220-1232. doi: 10.2214/AJR.07.3568
38. National Comprehensive Cancer Network: cancer-related fatigue. (2012). http://www.nccn.org/professionals/physician-gls/PDF/fatigue.pdf
39. Kollmannsberger C, Bjarnason G, Burnett P et al (2011) Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist 16(5):543-553. doi: 10.1634/theoncologist.2010-0263
40. Navari RM, Koeller JM (2003) Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother 37(9):1276-1286. doi: 10.1345/aph.1C510
41. Kappers MH, van Esch JH, Sluiter W et al (2010) Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 56(4):675-681. doi: 10.1161/HYPERTENSIONAHA. 109.149690
42. Chu TF, Rupnick MA, Kerkela R et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370(9604):2011-2019. doi: 10.1016/S0140-6736(07)61865-0
43. Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7(5):332-344. doi: 10.1038/nrc2106
44. Cheng H, Force T (2010) Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 106(1):21-34. doi: 10.1161/CIRCRESAHA.109.206920
45. Shinohara N, Takahashi M, Kamishima T et al (2011) The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br J Cancer 104(2):241-247. doi: 10.1038/sj.bjc.6606029
46. Desai J, Yassa L, Marqusee E et al (2006) Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145(9):660-664 (pii: 145/9/660)
47. Wong E, Rosen LS, Mulay M et al (2007) Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17(4):351-355. doi: 10.1089/thy.2006.0308
48. Mannavola D, Coco P, Vannucchi G et al (2007) A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92(9):3531-3534. doi: 10.1210/jc.2007-0586
49. Makita N, Miyakawa M, Fujita T et al (2010) Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid 20(3):323-326. doi: 10.1089/thy.2009.0414
50. Wolter P, Stefan C, Decallonne B et al (2008) The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 99(3):448-454. doi: 10.1038/sj.bjc.6604497
51. Schmidinger M, Vogl UM, Bojic M et al (2011) Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer (Phila) 117(3):534-544. doi: 10.1002/cncr.25422
52. Lessing C, Schmitz A, Albers B et al (2010) Impact of sample size on variation of adverse events and preventable adverse events: systematic review on epidemiology and contributing factors. Qual Saf Health Care 19(6):e24. doi: 10.1136/qshc.2008.031435
53. Romano PS, Chan BK, Schembri ME et al (2002) Can administrative data be used to compare postoperative complication rates across hospitals? Med Care 40(10):856-867. doi: 10.1097/01.MLR.0000027452.96163.A4
54. Bent S, Padula A, Avins AL (2006) Brief communication: better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med 144(4):257-261
55. Ioannidis JP, Mulrow CD, Goodman SN (2006) Adverse events: the more you search, the more you find. Ann Intern Med 144(4):298-300
56. Rosenzweig P, Brohier S, Zipfel A (1993) The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies. Clin Pharmacol Ther 54(5):578-583
57. Hillman SL, Mandrekar SJ, Bot B et al (2010) Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. J Clin Oncol 28(18):3002-3007. doi: 10.1200/JCO.2009.27.4282